- Home
- HNVR vs SGHT Comparison
HNVR vs SGHT Comparison
Compare HNVR & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HNVR
- SGHT
- Stock Information
- Founded
- HNVR 2008
- SGHT 2011
- Country
- HNVR United States
- SGHT United States
- Employees
- HNVR N/A
- SGHT N/A
- Industry
- HNVR Commercial Banks
- SGHT Medical Specialities
- Sector
- HNVR Finance
- SGHT Health Care
- Exchange
- HNVR Nasdaq
- SGHT Nasdaq
- Market Cap
- HNVR 167.7M
- SGHT 179.7M
- IPO Year
- HNVR 2022
- SGHT 2021
- Fundamental
- Price
- HNVR $21.51
- SGHT $4.20
- Analyst Decision
- HNVR Buy
- SGHT Buy
- Analyst Count
- HNVR 2
- SGHT 8
- Target Price
- HNVR $23.75
- SGHT $4.16
- AVG Volume (30 Days)
- HNVR 12.4K
- SGHT 129.3K
- Earning Date
- HNVR 07-23-2025
- SGHT 08-07-2025
- Dividend Yield
- HNVR 1.86%
- SGHT N/A
- EPS Growth
- HNVR N/A
- SGHT N/A
- EPS
- HNVR 1.53
- SGHT N/A
- Revenue
- HNVR $68,211,000.00
- SGHT $76,303,000.00
- Revenue This Year
- HNVR N/A
- SGHT N/A
- Revenue Next Year
- HNVR $13.97
- SGHT $11.22
- P/E Ratio
- HNVR $14.08
- SGHT N/A
- Revenue Growth
- HNVR 14.14
- SGHT N/A
- 52 Week Low
- HNVR $16.71
- SGHT $2.03
- 52 Week High
- HNVR $27.14
- SGHT $7.05
- Technical
- Relative Strength Index (RSI)
- HNVR 46.65
- SGHT 61.53
- Support Level
- HNVR $20.88
- SGHT $4.01
- Resistance Level
- HNVR $22.40
- SGHT $4.34
- Average True Range (ATR)
- HNVR 0.57
- SGHT 0.24
- MACD
- HNVR 0.08
- SGHT 0.09
- Stochastic Oscillator
- HNVR 47.79
- SGHT 88.62
About HNVR Hanover Bancorp Inc.
Hanover Bancorp Inc is a United States-based banking company. It offers a full range of financial services and employs a complete suite of consumer and commercial banking products and services, including multi-family and commercial mortgages, residential loans, business loans, and lines of credit.
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.